GLP Research Reports

Thursday, June 4, 2026

GLP-1 medicine improves liver health independent of weight loss

Lunenfeld-Tanenbaum Research Institute

Researchers at Toronto's Sinai Health have found that semaglutide – the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1 – acts directly on a subset of liver cells to improve organ function and does so independently of weight loss. The finding challenges long-held assumptions about how GLP-1 medicines work in the liver and could reshape how physicians treat metabolic liver disease.

For years, the liver benefits of semaglutide have puzzled scientists. The drug was known to lover blood sugar and promote weight loss, but patients’ livers were improving in ways that those effects alone could not explain.

“We’ve seen in clinical trials that patients who lose very little weight see the same reductions in liver inflammation, scarring and enzyme levels as those who lose a great deal of weight. Now we know why,” said Dr. Daniel Drucker, a senior investigator at the Lunenfeld-Tanenbaum Research Institute, who led the study.

Dr. Drucker’s has been at the forefront of GLP-1 research since the 1980s when his pioneering discoveries helped lay the groundwork for the development of GLP-1 medicines.

After transforming treatment of type 2 diabetes and obesity, semaglutide and other GLP-1 medicines have been approved for other conditions including MASH, for metabolic dysfunction-associated steatohepatitis. MASH is a severe form of fatty liver disease in which fat buildup, inflammation and tissue scarring can lead to cirrhosis and liver failure. It affects about 25 per cent of Canadian adults and because it is closely linked with obesity and type 2 diabetes, treatment typically includes lifestyle interventions to reduce weight.

Now Dr. Drucker and his team have revealed that semaglutide acts directly on the liver to reduce inflammation and scarring and improve organ function in a way that is independent of weight loss, as described in a paper published in Cell Metabolism.

Their finding overturns a prevailing assumption in the field that liver cells do not carry the receptor that semaglutide binds to, meaning the drug had no direct route to the organ.

Postdoctoral fellow Dr. Maria Gonzalez-Rellan spearheaded the work that combined sophisticated mouse models of MASH with deep molecular analyses of liver cells. Her work identified two cell types carrying semaglutide receptors: liver sinusoidal endothelial cells (LSECs) and immune T cells.

Although LSECs account for only about three per cent of liver cell volume, they proved to be the key driver of semaglutide’s liver benefits. LSECs line the tiniest blood vessels in the liver and are studded with pores that allow them to act as a molecular sieve, filtering substances passing between the liver and the bloodstream. Dr. Gonzalez-Rellan showed that semaglutide reversed MASH in mice that lacked the brain receptors controlling appetite demonstrating that weight loss is not required for liver benefits. In a further test, mice lacking LSEC receptors showed no liver improvement on semaglutide even after losing 20 per cent of their body weight.

Detailed molecular analyses of liver cell types showed that semaglutide shifts gene activity in LSCEs, prompting them to release anti-inflammatory molecules that act on the broader liver environment, pushing it toward a state more closely resembling a healthy, disease-free liver.

“It turns out that the receptor responsible for these benefits is in a very specialized population of liver cells. And this receptor orchestrates the production of molecules that talk to many different types of liver cells to calm down the inflammatory environment that is the problem in metabolic disease,” said Dr. Drucker, who is also a University Professor of medicine at the University of Toronto.

The findings carry practical implications. GLP-1 medicines have become widely prescribed, yet their mechanism of action in the body, beyond appetite suppression and blood sugar control, have remained incompletely understood. Knowing that semaglutide improves liver health independently of weight loss could influence prescribing decisions. Physicians may choose lower doses that avoid the side effects associated with the higher doses needed for significant weight loss, potentially also lowering costs for patients, said Dr. Drucker.

He added, “We're not saying weight loss isn't important because many things improve when patients lose weight. But we now know that weight shouldn't be the only measure of success, because GLP1 medicines will improve liver health whether or not the patient loses weight.”

Journal

Cell Metabolism

DOI

10.1016/j.cmet.2026.03.011

Weight-loss drugs could tackle Alzheimer’s – study

A new study has found comprehensive evidence that ‘weight-loss’ GLP-1 receptor agonists such as semaglutide are effective in tackling the biological drivers of Alzheimer’s disease.

The study, published in the journal Molecular and Cellular Neuroscience, examined 30 preclinical studies investigating the effects of four GLP-1 receptor agonists – liraglutide; semaglutide; exenatide; and dulaglutide – on Alzheimer’s disease pathology.

The researchers, from Anglia Ruskin University (ARU), found consistent evidence from animal and cell studies that these drugs, commonly prescribed for people living with type 2 diabetes, reduce the buildup of amyloid‑beta and tau, the two hallmark proteins linked to the development and progression of Alzheimer’s.

The review found 22 studies showed reductions in amyloid‑beta, a protein that forms sticky plaques in the brain. 19 studies found reductions in hyperphosphorylated tau, the form of tau protein that creates harmful tangles within neurons. Liraglutide, the most extensively studied drug, consistently reduced both amyloid‑beta and tau pathology.

Dulaglutide and semaglutide also demonstrated positive effects on these proteins, though fewer studies were available. Exenatide studies yielded mixed results, with some showing reductions in amyloid or tau and others showing no effect.

Evidence in humans is still emerging. Of the two clinical trials that featured in the study, a 26‑week trial of liraglutide found no reduction in amyloid levels or cognitive improvement, but did show preservation of brain glucose metabolism, an indicator of neuronal function. An 18‑month trial of exenatide showed no significant changes in amyloid or tau in cerebrospinal fluid – the clear liquid that surrounds and protects the brain – but did reduce amyloid‑beta in extracellular vesicles, a potential early biomarker.

Alzheimer’s disease is the most common form of dementia in the UK, affecting around 900,000 people. The number is expected to rise significantly over the next decade. Despite decades of research, effective treatments remain limited.

Lead author Dr Simon Cork, Physiology lead at Anglia Ruskin University’s School of Medicine, said: “This new review provides one of the most comprehensive analyses so far of how GLP‑1 drugs interact with the underlying mechanisms of Alzheimer’s.

“Our study highlights several biological pathways by which GLP‑1 drugs may influence Alzheimer’s, including reducing inflammation, improving insulin signalling in the brain, and altering enzymes involved in the production of amyloid‑beta.

“Whilst human studies demonstrating an impact on cognitive decline are still lacking, the current evidence points towards these drugs having a preventative effect, rather than in patients with established cognitive impairment.

“With more than three‑quarters of preclinical studies showing reductions in amyloid‑beta or tau, and early signals emerging from studies on humans, GLP‑1 drugs remain strong candidates for future Alzheimer’s prevention trials. Larger, early‑stage clinical trials are now needed to determine whether these promising signs actually translate into tangible benefits for patients.”

Journal

Molecular and Cellular Neuroscience

DOI

10.1016/j.mcn.2026.104091

Method of Research

GLP-1 drugs have long-term benefit for heart health

New research has shown that GLP‑1 weight-loss drugs deliver protection against heart attacks, strokes and premature death over a sustained period of time.

Researchers from Anglia Ruskin University (ARU) analysed data from more than 90,000 patients enrolled in large-scale international studies and found that people given glucagon-like peptide‑1 (GLP‑1) receptor agonists were significantly less likely to suffer major cardiovascular events than those given a placebo.

The review of 11 major cardiovascular outcome trials, published in the journal Cardiovascular Diabetology – Endocrinology Reports showed treatment with GLP‑1 receptor agonists reduced the risk of major adverse cardiovascular events, such as heart attack, stroke and cardiovascular death, by approximately 13% compared with placebo over an average follow‑up of almost three years.

The research is significant because it has focused on the long-term benefits of the drug – only studies with a minimum of one year follow-up were considered. The results are also independent of whether or not a patient is diabetic.

Patients taking the drugs were also less likely to die from any cause, and experienced lower rates of non‑fatal heart attacks, non‑fatal strokes and hospital admissions for heart failure.

The benefits were seen in people already at high cardiovascular risk, including those with type 2 diabetes, obesity or existing heart disease.

The review found no meaningful increase in serious safety concerns, such as severe hypoglycaemia or acute pancreatitis, compared with placebo. Gastrointestinal side effects, including nausea and vomiting, were more common, but are already well recognised.

GLP‑1 receptor agonists include medications such as semaglutide, liraglutide and dulaglutide, have attracted widespread attention in recent years because of their effectiveness in treating obesity.

Lead author Dr Simon Cork, Physiology lead at Anglia Ruskin University’s School of Medicine, said: “This is the most comprehensive review to date of long‑term cardiovascular outcome trials for GLP‑1 receptor agonists. We know that one of the factors that weighs on people’s minds when considering going onto these drugs is the potential long-term side effects.

“Our results show that, when taken over a prolonged period of at least one year, these medications do much more than help control blood sugar or weight. They significantly reduce the risk of heart attacks, strokes and premature death in people who are already vulnerable.

“We found the benefits to be consistent across different drugs, trial designs and patient groups. This has important implications for clinical practice and health policy, particularly given cardiovascular disease is the leading cause of death in the UK.

“These drugs have the potential to become a key part of healthcare strategies, especially for people with type 2 diabetes or established heart disease. Using them earlier and more widely across populations could help prevent thousands of serious cardiovascular events.”

Journal

Cardiovascular Diabetology – Endocrinology Reports

DOI

10.1186/s40842-026-00295-3

Popular weight loss, diabetes drugs linked to improved breast cancer survival

New research published today in JAMA Network Open offers illuminating evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.

“This study suggests that GLP-1 drugs may offer protective benefits potentially improving survival and recurrence risk in some female patients with breast cancer – whether this is related to weight control, improve cardiovascular health or other mechanisms remains to be studied,” said study senior author Bernard F. Fuemmeler, Ph.D., MPH, associate director for population sciences and the Gordon D. Ginder, M.D., Chair in Cancer Research at VCU Massey Comprehensive Cancer Center.

The research findings
Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes.

GLP-1 RA use was associated with an overall lower risk of death from any cause over a 10-year follow-up period among breast cancer patients. Additionally, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.

“Our findings align with emerging preclinical research and contribute to a growing body of literature related to GLP-1 RA use in oncology settings,” said study lead author Kristina L. Tatum, PsyD, MS, of the VCU School of Public Health.

What’s next?
Further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes. The research team intends to further evaluate these correlations through randomized clinical trials.

“Our study underscores the potential of GLP-1 RAs as an adjunct strategy for improving cancer-related outcomes among patients with breast cancer, although clinical trials are needed to inform effective therapeutic approaches and clinical decision making,” Fuemmeler said.

About breast cancer

The most common cancer among women in the US, except for skin cancer, accounting for nearly one-third of all female cancer cases.
The average risk of a woman in the US developing breast cancer sometime in her life is about 13%.

Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.

What are GLP-1 drugs?

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
Approved to treat type 2 diabetes in 2005 and weight management in 2021.
Impacts on breast cancer survival and recurrence are still unclear.

Since 2020, the use of these drugs has increased dramatically, where approximately 12% of Americans have used GLP-1s for weight loss, according to a RAND report.

Journal

JAMA Network Open

DOI

10.1001/jamanetworkopen.2026.12133

Muscle mass preserved after obesity drug treatment

New research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that following treatment with GLP-1 drugs for obesity, most weight loss is fat mass (80–85%) and relative muscle mass is preserved. The study is by Emilia Ida Frohner, Dr Alexander Jürets and Dr Bianca Karla-Itariu, Metabolism Center N°12 Antonigasse, Vienna, Austria and Medical University of Vienna, Austria.

Multiple clinical trials have shown glucagon-like peptide-1 (GLP-1)-based treatments (semaglutide/liraglutide) and GIP/GLP-1 (glucose-dependent insulinotropic polypeptide) dual agonists (tirzepatide) are safe and lead to weight reduction and decreased risk for adverse clinical outcomes. However, researchers are still trying to understand the relative effects on muscle and fat mass as a person loses weight using these drugs.

Bioelectrical Impedance Analysis (BIA) is a non-invasive, fast, and relatively inexpensive method for estimating body composition—including body fat, lean muscle mass, and water—by sending a low-level electrical current through the body. It relies on the principle that lean tissue conducts electricity better than fat.

Understanding changes in body composition, rather than weight alone, is essential to evaluate treatment quality and long-term functional outcomes using obesity drugs. In this new study, the authors analysed changes in skeletal muscle mass and fat mass during GLP-1RA or GIP/GLP-1RA therapy in adults with obesity using bioelectrical impedance analysis (BIA), and to evaluate the relationship between fat loss and muscle mass preservation over time.

This retrospective cohort study included 486 adult patients with obesity (18% male, 82% female; mean BMI 37.68 kg/m²; mean age 49.9 years) treated with GLP-1 receptor agonists or GIP/GLP-1 receptor agonists (liraglutide [8%], semaglutide [82%], or tirzepatide [8%]) at a specialised private obesity outpatient clinic in Vienna between 2022 and 2025. All patients received recommendations regarding physical exercise as per current guidelines. Body composition was assessed using bioelectrical impedance analysis (BIA), a non-invasive method for estimating fat and muscle mass.

Changes in absolute and relative skeletal muscle mass and fat mass from baseline to follow-up were analysed across different treatment durations (<6 months, 6–24 months, >24 months). If multiple measurements were available within a predefined time window, a single measurement per individual was selected based on the longest time since baseline. Computer modelling to adjust for repeated measurements was applied and adjusted for fat mass, time since treatment initiation, age, sex, and baseline BMI.

After a mean treatment duration of approximately 14 months, patients achieved a mean weight loss of 9.9%. Fat mass decreased by 9.0 kg (around 18%), while skeletal muscle mass decreased by only 1.2 kg (around 5%). Relative skeletal muscle mass was preserved or increased in more than 70% of patients. Statistical modelling showed that muscle mass remained stable over time when accounting for changes in fat mass, suggesting favourable body composition changes rather than clinically relevant muscle wasting.

In adjusted linear mixed-effects models, time since treatment initiation was not independently associated with skeletal muscle mass after accounting for fat mass and other variables. Fat mass was strongly associated with absolute skeletal muscle mass, indicating proportional changes in body composition rather than disproportionate muscle loss.

The authors say: “In this real-world cohort, GLP-1RA or GIP/GLP-1 RA therapy was associated with substantial fat mass reduction while largely preserving skeletal muscle mass in relative terms. Our analyses indicate that skeletal muscle mass remains stable over time when accounting for changes in fat mass, supporting the concept that GLP-1RA-induced weight loss reflects favourable body composition changes rather than clinically relevant muscle wasting.”

The authors note that this is a retrospective real-world study with inherent limitations, including missing data, no placebo group, and a predominantly female study population. The findings apply to this specific treatment group and duration; larger prospective trials are needed to assess long-term effects.

GLP-1 class of obesity drugs significantly help people with asthma attacks

Facebook

New research presented at this year’s European Congress on Obesity in Istanbul, Turkey (12-15 May) shows the use of the new GLP-1 class of obesity drugs in people with asthma is associated with a 26% fall in the number of asthma exacerbations and a 14% drop in use of asthma inhaler reliever use. The study is by Simon Høj and Dr Kjell Erik Julius Håkansson Copenhagen University Hospital, Copenhagen Denmark and colleagues.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now widely used to treat overweight, obesity and type 2 diabetes (T2DM), with growing evidence of benefits that extend beyond blood sugar control.

In asthma, where overweight, obesity and metabolic dysfunction can lead to increased severity of symptoms and adverse events such as acute exacerbations, the authors suggest that GLP-1 RAs may improve asthma outcomes through weight loss, modulation of airway inflammation, and improvements in metabolic functions. Reductions in occurrence of asthma exacerbations are likely to reduce systemic corticosteroid exposure (a common treatment for acute asthma exacerbations orally or intravenously) and thus may reduce the risk of corticosteroid exposure-associated adverse events such as osteoporosis or new-onset T2DM. As such, as the clinical use of GLP-1 RAs expands, reliable estimates of their impact on asthma control are needed for individuals living with both asthma and overweight, obesity or T2DM.

The researchers conducted a nationwide self-controlled cohort study using linked Danish health registers. Adult individuals with a prior asthma diagnosis or ≥2 asthma inhaler prescriptions redeemed within 12 months) were included on the date of their first GLP-1 RA dispensing (index date). Eligible individuals had continuous registration data for at least 12 months before and after the index date.

Individuals with COPD or patients with severe asthma treated with new and relatively expensive biologic drugs within 12 months before or after the index date were excluded. Overweight or obesity was defined using ICD-10 codes for those conditions. Those who had no evidence of T2DM - with no diagnosis recorded or no evidence of other first line diabetes drugs prescribed - were also placed in the with obesity/overweight group. Those with a T2DM diagnosis or prescriptions recorded for first line diabetes drugs such as metformin were placed in the T2DM group.

The primary outcome was exacerbations, defined as an inpatient asthma hospital contact(s) and/or systemic oral or intravenous corticosteroid course(s). Secondary outcomes were the use of rescue medication (inhaled short-acting β2-agonists), inhaled corticosteroid exposure, and chest infection events defined as redemption of antibiotics commonly used for lower airway infections

The cohort comprised 27,523 individuals (mean age 54 years, 66% female) with asthma and comorbid overweight or obesity (49%) or T2DM (61%) and 26% recorded as having both conditions. Around 50% of the GLP-1 prescriptions were liraglutide, 48% semaglutide, and 2% others (exenatide, dulaglutide, lixisenatide).

Compared with the year before GLP-1 RA treatment, GLP-1 RA treatment was associated with a 26% lower exacerbation rate overall; and 28% lower in men compared with 23% lower in women. When stratified according to GLP1 RA treatment indication, the analysis showed individuals with asthma and comorbid overweight or obesity and individuals with asthma and comorbid T2DM had similar effect estimates – a 22% reduction in those with overweight or obesity and a 26% reduction in those with T2D.

Reliever medication use fell by 14% overall, suggesting fewer symptoms despite daily inhaled corticosteroid exposure also decreasing by 23% (inhaled corticosteroids are used to prevent exacerbations and treat symptoms in asthma). Furthermore, pneumonia events were reduced by 10%. People also living with allergic rhinitis saw similar decreases (23%) in exacerbations to those living without allergic rhinitis (28%). The authors are also working on updated analyses to show differences between men and women for these specific outcomes.

The authors conclude: “In this nationwide cohort of over 27,000 individuals with asthma and also overweight, obesity or type 2 diabetes, use of GLP-1 drugs was associated with significant reductions in exacerbation burden as well as reliever use, exposure to inhaled corticosteroids and pneumonia events, irrespective of whether the drugs were being used to treat obesity or type 2 diabetes.”

The authors explain that their study did not have access to clinical records (just if people had used GLP-1 and hospital admissions), so data on BMI and weight loss for participants were not available.

But Dr Håkansson says: “There's a high chance that the weight loss is a major contributor to these results. A common symptom in both asthma and obesity is shortness of breath, and the presence of excess fatty tissue creates a pro-inflammatory state in the body in general. There's also evidence from other studies suggesting that the inflammation caused by excess adipose tissue is distinct from the ‘classic’ asthma inflammation which often is driven by allergies or cells called eosinophils.”

And he adds: “As the use of GLP-1 therapies increase, researchers are finding an increasing number of effects outside of weight loss.”

Extending healthspan via GLP-1 receptor agonist

Aging is characterized by chronic inflammation, oxidative stress, and mitochondrial dysfunction. Glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs), developed for type 2 diabetes and obesity, may modulate the hallmarks of aging. This review summarizes mechanistic and therapeutic evidence that GLP‑1 RAs improve mitochondrial function, reduce oxidative stress, enhance autophagy, and attenuate inflammaging. Preclinical and clinical data indicate neuroprotective, cardioprotective, and metabolic benefits. GLP‑1 RAs affect all 12 hallmarks of aging, including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, insulin resistance, and dysbiosis. Although long‑term safety requires further evaluation, GLP‑1 RAs are promising gerotherapeutics with potential to extend healthspan.

Introduction
Aging involves progressive physiological decline and increased chronic disease risk. The twelve hallmarks of aging provide a framework for understanding molecular mechanisms. GLP‑1 is an incretin hormone that enhances insulin secretion, suppresses glucagon, and delays gastric emptying. GLP‑1 RAs resist DPP‑4 degradation and have shown benefits beyond glycemic control, including cardiovascular and neuroprotective effects. This review explores how GLP‑1R signaling may influence aging pathways and promote healthy aging.

GLP‑1R Signaling in Healthy Aging
GLP‑1R is a G‑protein‑coupled receptor in pancreas, brain, gut, and other tissues. Activation triggers cAMP/PKA, Epac/PI3K/Akt, and ERK/MAPK pathways. These pathways enhance mitochondrial biogenesis, autophagy, cell survival, and stress resistance. GLP‑1R also modulates sirtuins (SIRT1), NAD⁺ metabolism, and the HPA axis, linking metabolic health to neuroendocrine resilience. Cardiovascular benefits include improved endothelial function, reduced arterial stiffness, and lower MACE risk (~14% reduction in meta‑analyses).

GLP‑1 RAs and the Hallmarks of Aging
GLP‑1 RAs affect all twelve hallmarks:

Genomic instability: Reduce oxidative DNA damage via AMPK and enhance DNA repair.
Telomere attrition: May preserve telomere length by reducing metabolic stress and upregulating SIRT1.
Epigenetic alterations: Reverse aberrant DNA methylation of the GLP‑1R gene and influence histone modifiers.
Loss of proteostasis: Enhance autophagy (AMPK/mTOR pathway) to clear misfolded proteins.
Deregulated nutrient sensing: Improve insulin sensitivity, suppress mTOR overactivation, and mimic caloric restriction effects.
Mitochondrial dysfunction: Promote biogenesis (PGC‑1α), increase respiration, and reduce ROS.
Cellular senescence: Lower oxidative stress and inflammation, reducing senescent cell burden.
Stem cell exhaustion: Protect stem cell function via reduced inflammation and improved vascular niche.
Altered intercellular communication: Reduce inflammatory cytokines (TNF‑α, IL‑6) and improve endothelial function.
Inflammaging: Decrease systemic and neuroinflammation.
Dysbiosis: Modify gut microbiota composition, increasing beneficial bacteria and reducing gut permeability.
Disabled macroautophagy: Restore autophagic flux.

Clinical trials (STEP, SURMOUNT, SELECT) show GLP‑1 RAs induce weight loss, improve cardiovascular outcomes, and reduce all‑cause mortality. However, lean mass loss occurs (2–4 kg in major trials), necessitating protein intake (1.0–1.2 g/kg/day) and resistance exercise, especially in older adults. The SEMALEAN study found improved muscle function despite initial lean mass loss.

Emerging Hypotheses and Limitations
GLP‑1R activation may have organ‑specific effects due to differential aging rates (e.g., brain, kidney, heart). Individual variability in aging trajectories requires personalized dosing and monitoring. Chronic use may lead to receptor desensitization or gastrointestinal adverse events. Long‑term safety data in healthy, non‑obese older adults are lacking. Evidence for healthspan extension beyond metabolic benefits remains indirect; functional endpoints (frailty, cognition, mobility) need more study.

Clinical Uses and Obesity Link
Obesity accelerates aging via inflammation and metabolic dysfunction. GLP‑1 RAs reduce weight, improve insulin sensitivity, and lower biological age (epigenetic clocks). In HIV‑associated lipohypertrophy, semaglutide slowed epigenetic aging. Tirzepatide reduced left ventricular mass in heart failure. Ongoing trials are evaluating physical function and frailty outcomes.

Future Directions

Standardize biomarkers of aging (epigenetic, proteomic clocks).
Conduct long‑term RCTs in older adults with functional endpoints (cognition, gait speed, frailty).
Develop precision medicine approaches based on organ‑specific aging profiles.
Investigate combination with exercise and nutritional support to preserve lean mass.
Address global access and health equity.

Conclusions
GLP‑1 RAs exert pleiotropic effects across all 12 hallmarks of aging. They improve mitochondrial function, reduce inflammation, enhance autophagy, and support metabolic and cardiovascular health. While long‑term safety and efficacy in healthy aging populations require further validation, current evidence positions GLP‑1 RAs as promising gerotherapeutics to extend healthspan and mitigate age‑related decline.

Full text:

https://www.xiahepublishing.com/2472-0712/ERHM-2025-00036

The study was recently published in the Exploratory Research and Hypothesis in Medicine.